Ciprofloxacin is indicated for the treatment of infections caused by susceptible isolates of an resistant organism (ciprofloxacin-S3) or infections caused by the well characterizedS. aureusinfection S aureus. Swine infections are indicated for the treatment of infections caused by resistant to ciprofloxacin-S3 and for the treatment of patients with S aureus associated with decreased natural Killer (Sik) function. Treatment of infections caused by susceptiblein horses with infections caused by ciprofloxacin-S3 is indicated in those patients who have sufficientgen� anddoi of thegroup to determine whether the drug will be effective in eradicating the eradicated.
Ciprofloxacin-S3:Adults:1-8 kg:1 x 200 mg dose. Acute otitis media: 1-2 kg: 1-2 g dose. Chronic otitis media: 1-2 g/day1-4.5-5.5 x 200 mg: 2-4 g dose. Skin and soft tissue infections: 1-2.5 g/day 1-4.5 x 200 mg: 1-2 g/day 2-4 x 200 mg: 1-2.5 g/day or x 200 mg: 1-2.5 g/day as directed by the physician.
Inhalational Anthrax (15 g/day): in adult horses 1-2.5 g/day. Respiratory Tract Infection: 8-30 g/day:1-2.5 g/day;Skin and soft tissue infections: 1-2.5 g/dayAcute Otitis Media: 1-2.5 g/dayChronic Otitis Media: 1-2 g/daySkin and soft tissue infections: 1-2 g/dayAcute Sinusitis: 1-2 g/dayRespiratory Tract Infection: 8-30 g/day
1. Dose in pediatric patients: 10-40 g/kg/day.
Dosage:Children 1-2.5 kg 2-4 g x 200 mg: 1-2 g/day. Children 5-9 kg 10 g 10-19 mg/kg/day. For the treatment of chronic bronchitis 2-10 g/day: 1-2.5 g/day. For the treatment of pulmonary edema 10-19 mg/kg/day.
In the UK:
Ciprofloxacin is considered to be contraindicated in horses with a history of infectious mononucleosis (mononucleosis) or diphtheria, tetanus, measles, or influenza, as these horses are less susceptible to some of the other quinolone antibiotics including erythromycin and clarithromycin. The use of quinolones in horses with diphtheria, measles, or influenza will not be recommended.
Inhalational Anthrax (15 g/day): in adult horses 1-2.
The first-line therapy for patients with urinary tract infections (UTIs) is the ciprofloxacin oral suspension. Ciprofloxacin has received attention as a suitable treatment for UTIs in adult patients. Although ciprofloxacin has a relatively low incidence of adverse effects, the clinical efficacy and tolerability of ciprofloxacin were poor. A randomized study of ciprofloxacin versus placebo in adult patients with UTIs with no evidence of an adverse event was conducted in the phase II trial. The patients were randomized to receive either ciprofloxacin (10 mg, 40 mg, and 60 mg, twice daily for 10 days) or placebo for 10 days, as a continuous regimen for a minimum of 5 days. The objective of the study was to determine the tolerability and efficacy of ciprofloxacin to a randomized, double-blind, placebo-controlled trial of 10 patients with no evidence of an adverse event. In the subgroup of patients in whom ciprofloxacin was superior to placebo, a primary efficacy endpoint was defined as change from baseline in the International Index of Erectile Function Domain (IIEF-EF). The IIEF-EF showed a good to excellent reliability to detect differences from the primary endpoint.
The study was a single-center, randomized, double-blind, placebo-controlled trial. The primary efficacy endpoint was the change from baseline in the IIEF-EF in patients who received ciprofloxacin and those who received placebo. A secondary efficacy endpoint was defined as a decrease in the IIEF-EF score from baseline to 1 point after treatment in patients with a low-grade infection. The secondary efficacy endpoint was defined as a change from baseline in the IIEF-EF score in patients who received ciprofloxacin and who received placebo. In the subgroup of patients with a low-grade infection who received ciprofloxacin, the primary endpoint was defined as a decrease from baseline in the IIEF-EF score in patients who received ciprofloxacin and who received placebo. In the subgroup of patients with a low-grade infection who received placebo, the primary endpoint was defined as a decrease from baseline in the IIEF-EF score in patients who received ciprofloxacin and who received placebo. There were no significant differences between the subgroup of patients in whom ciprofloxacin was superior to placebo and those who received ciprofloxacin.
The primary efficacy endpoints were an IIEF-EF score of at least 1 point at the first follow-up, and a change from baseline from baseline to the first follow-up at a rate of 0.2 percent/h on the first visit. In the subgroup of patients who received ciprofloxacin, the primary endpoint was an improvement from baseline in the IIEF-EF score. In the subgroup of patients who received placebo, the primary endpoint was defined as a decrease from baseline in the IIEF-EF score in patients who received placebo. In the subgroup of patients who received ciprofloxacin, the primary endpoint was defined as a decrease from baseline in the IIEF-EF score in patients who received ciprofloxacin and who received placebo. The secondary endpoints were the change from baseline in the IIEF-EF score from baseline to the first follow-up, the change from baseline to the first follow-up, and the change from baseline to the first visit. The primary efficacy endpoints were the IIEF-EF score of the first follow-up, and a change from baseline from baseline to the first follow-up at a rate of 1 point on the first visit. The secondary endpoints were the IIEF-EF score of the first follow-up, and the change from baseline to the first follow-up at a rate of 0.2 percent/h on the first visit. The subgroup of patients who received ciprofloxacin showed a better tolerability and efficacy than patients who received placebo. The study is in part funded by a grant from the USFDA (grant number: FAPESP).
Abdel-Qadir, M. A., and Zaman, M. A. (2004). Antimicrobial and non-steroidal anti-inflammatory drugs and the risk of renal and/or hepatic toxicity.Clin Ther. 10:e00159-e00174.
Treatment of bacterial infections of the lungs, nose, ear, bones and joints, skin and soft tissue, kidney, bladder, abdomen, and genitals caused by ciprofloxacin-susceptible organisms. Infections may include urinary tract infection, prostatitis, lower respiratory tract infection, otitis media (middle ear infection), sinusitis, skin, bone and joint infections, infectious diarrhea, typhoid fever, and gonorrhea.
May be taken with or without food. May be taken w/ meals to minimise GI discomfort. Do not take w/ antacids, Fe or dairy products.
Hypersensitivity to ciprofloxacin or other quinolones. History or risk of QT prolongation; known history of myasthenia gravis. Concomitant use with tizanidine.
Vomiting, Stomach pain, Nausea, Diarrhea
Patient with known or suspected CNS disorders, risk factors predisposing to seizures, or lower seizure threshold; history or risk factors for QT interval prolongation, torsades de pointes, uncorrected hypokalaemia/hypomagnesaemia, cardiac disease (e.g. heart failure, MI, bradycardia); positive family history of aneurysm disease, pre-existing aortic aneurysm or dissection and its risk factors (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, hypertension, peripheral atherosclerotic vascular disease); diabetes, previous tendon disorder (e.g. rheumatoid arthritis), G6PD deficiency. Renal and hepatic impairment. Elderly, children. Pregnancy and lactation.
Store between 20-25°C.
Quinolones
Viagra®MedsGo class C ciprofloxacin: See MCS for Pregnancy and Lactation
CiproGeneralised tonic-clonic Forces (GTC)Management of respiratory tract infections:Antimicrobial therapy is recommended for most infections, usually following the initial treatment of sinusitis. For infections due toS. aureus, therapy should be limited to treatment of the infection site at the time of initial empirical therapy, with a high degree of success achieved only forrequently treated infections. Some respiratory tract infections may require surgical repair, while others may be repairable. Surgical technique is more effective in certain infections, such as those causing sinusitis, and may be more difficult to treat in these cases. For infections with gram-positive and gram-negative organisms, therapy should be limited to treatment of the infection site at the time of initial empirical treatment, with a high degree of success achieved only forrequently treated infections. For other infections, NRT may be required, with therapy for initial and recurrent infections extending beyond the eradication of gram-positive and gram-negative organisms.
Rhabdomyolysis (RXL) caused byRARsinusManagement of acute otitis media (AOM):The recommended dosage is an oral dose of 500 mg bid, as this should be given concurrently with a single dose of 1 g of ciprofloxacin. Therapy should be initiated with a single 500 mg dose of ciprofloxacin, and therapy should be extended to 1 g bid. Care should be taken to maintain therapeutic levels, but in patients with a positive family history of AOM, this medicine may be used off-label for RXL. RXL can sometimes lead to irreversible damage to the middle ear, and this may be done by elect to continue therapy with ciprofloxacin (see Pharmacology: Pharmacodynamics: Clinical and Experimental Studies under Actions).
Treatment of bacterial infections of the lungs, nose, ear, bones and joints, skin and soft tissue, kidney, bladder, abdomen, and genitals caused by ciprofloxacin-susceptible organisms. Infections may include urinary tract infection, prostatitis, lower respiratory tract infection, otitis media (middle ear infection), sinusitis, skin, bone and joint infections, infectious diarrhea, typhoid fever, and gonorrhea.
May be taken with or without food. May be taken w/ meals to minimise GI discomfort. Do not take w/ antacids, Fe or dairy products.
Hypersensitivity to ciprofloxacin or other quinolones. History or risk of QT prolongation; known history of myasthenia gravis. Concomitant use with tizanidine.
Vomiting, Stomach pain, Nausea, Diarrhea
Patient with known or suspected CNS disorders, risk factors predisposing to seizures, or lower seizure threshold; history or risk factors for QT interval prolongation, torsades de pointes, uncorrected hypokalaemia/hypomagnesaemia, cardiac disease (e.g. heart failure, MI, bradycardia); positive family history of aneurysm disease, pre-existing aortic aneurysm or dissection and its risk factors (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, hypertension, peripheral atherosclerotic vascular disease); diabetes, previous tendon disorder (e.g. rheumatoid arthritis), G6PD deficiency. Renal and hepatic impairment. Elderly, children. Pregnancy and lactation.
Store between 20-25°C.
Quinolones
uses a class of>Tazobactrimciprofloxacin: a broad spectrum of activity against a wide range of Gram-positive and Gram-negative bacteria. The activity against Enterobacteriaceae is most effective against Staphylococcus aureus and Haemophilus influenzae. The activity against Proteus mirabilis is most effective against Streptococcus pneumoniae. The activity against Streptococcus pyogenes is most effective against Staphylococcus saprophyticus. The activity against Pseudomonas aeruginosa is most effective against Haemophilus influenzae. The activity against Streptococcus group B Streptococci is most effective against Haemophilus influenzae. The activity against Staphylococcus epidermidis is most effective against Streptococcus epidermidis.Cases of squamous cell carcinoma of the head and neck, breast, prostate, and skin.
Serum cisapride or patent ductus arteriosus in patients with hepatic impairment. Hepatic impairment may cause dizziness or anaphylaxis. Patients with severe renal impairment may experience worsening renal function. Patients with severe hepatic impairment may experience, or are at risk of, jaundice or cardiac insufficiency. Hepatic insufficiency has been reported in patients taking warfarin, other anticoagulants, and in patients with pre-existing liver disease. Patients with hereditary hepatic disease may be at higher risk of developing this condition. Patients with severe renal insufficiency may experience, or are at risk of developing, hepatic impairment. Patients with breast cancer or other malignancy should be evaluated for the development of these conditions. Patients with porphyria should be advised to use warfarin and other anti-IgE medications concomitantly. Hepatic insufficiency has been reported in patients taking anti-IgE medications concomitantly. Hepatic insufficiency has been observed in patients taking warfarin, other anticoagulants, and in patients with pre-existing liver disease.
Stade de France Pharmacy